Humira The drug that caused the most increased spending by far was Humira, a rheumatoid arthritis drug. (Photo: JB Reed/Bloomberg)

Drug price increases that were not supported by clinical improvements raised health care costs in the U.S. by about $1.67 billion in 2020, a new report said.

The report, released by The Institute for Clinical and Economic Review (ICER) said that among the top 10 drugs with price increases last year that had substantial effects on US spending, seven of 10 drugs did not have new evidence of a new clinical benefit. The group said these unsupported drug price increases cost the U.S. health system $1.67 billion, even after pharmaceutical rebates and other concessions.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

BenefitsPRO Broker Expo 2024Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.